U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06967805) titled 'WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)' on April 14.
Brief Summary: A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Idiopathic Pulmonary Fibrosis
Intervention:
BIOLOGICAL: MTX-463
MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certai...